RxDoctor Payments Data

Bobbak Mansouri, MD

Dermatology · Conroe, TXNPI 1053604389

Payments from drug & device makers

$16,428in general payments, 2019–2025

Across 923 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$2K
  • Lilly USA, LLC$2K
  • Johnson & Johnson$1K
  • Sanofi$878
  • Pfizer$811
  • plus $7K from 30 others

What the payments were for

  • Food & beverage$16,22799%
  • Education$2011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,428 in reported general payments places this provider in the 80th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$330,255
Medicare patients
808
Services billed
5,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$230,138
TremfyaGuselkumab15$210,599
Cosentyx Unoready PenSecukinumab18$183,350
Dupixent PenDupilumab25$94,234
Clobetasol Propionate298$12,608
Ketoconazole180$2,991
Doxycycline Monohydrate133$2,464
Triamcinolone Acetonide189$2,140
Fluorouracil33$2,132
Tacrolimus14$1,506
Metronidazole28$1,496
Mycophenolate Mofetil15$1,290
Betamethasone Dipropionate36$1,183
Tretinoin13$1,120
Clindamycin Phosphate35$970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,240$210,59915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Conroe

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →